Replies to post #3834 on Insmed Inc (INSM)

[wjlknew]

<I think the PR only talks about short stature because it is the only approved drug they have for that indication.>

You are probably right. And, some seem to be losing sight of the fact that it will probably be a couple of years before Iplex is approved for anything BUT short stature. During that time, Insmed's net sales will probably not even approach $100 million ... much less $200 million ... so the royalty paid will neither be a windfall for TRCA nor a killer for INSM. By that time, the appeal will be settled.

The bottom line is that TRCA will receive (and INSM will pay) very little from the royalty for some time ... if ever.